US equities
|
MU
$914.13
▲+0.00%
SNDK
$1,403.34
▲+0.00%
SKHY
$147.55
▲+0.00%
NVDA
$221.30
▲+0.00%
TSM
$430.00
▲+0.00%
SPCX
$152.16
▲+0.00%
INTC
$98.00
▼-0.12%
AMD
$570.82
▲+0.00%
MU
$914.13
▲+0.00%
SNDK
$1,403.34
▲+0.00%
SKHY
$147.55
▲+0.00%
NVDA
$221.30
▲+0.00%
TSM
$430.00
▲+0.00%
SPCX
$152.16
▲+0.00%
INTC
$98.00
▼-0.12%
AMD
$570.82
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Aldeyra Therapeutics, Inc. - Common Stock
(NQ:
ALDX
)
0.7904
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 14, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aldeyra Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
4 Biotech Stocks Seeing Explosive Momentum Gains
↗
October 07, 2025
The SPDR S&P Biotech ETF (ARCA:XBI) is up more than 40% over the past six months and is on the verge of breaking out. Here's a look at several momentum standouts in the biotech space that appear to be...
Via
Benzinga
Topics
ETFs
Stocks
Aldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
September 03, 2025
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma
August 28, 2025
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa
August 19, 2025
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
August 06, 2025
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa
July 24, 2025
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease
July 17, 2025
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma
June 26, 2025
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
June 17, 2025
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference
May 29, 2025
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
May 18, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Organon, Aldeyra, Landstar, and ICU Medical and Encourages Investors to Contact the Firm
May 14, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra Therapeutics, Inc. – ALDX
May 13, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
May 09, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating RobinHood, Aldeyra, Landstar, and ICU Medical and Encourages Investors to Contact the Firm
May 07, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
May 06, 2025
Via
Benzinga
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission
May 05, 2025
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap
May 05, 2025
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
May 05, 2025
From
Pomerantz LLP
Via
GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
↗
May 05, 2025
Via
Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
April 29, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm
April 28, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
Rosen Law Firm Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – ALDX
April 25, 2025
From
The Rosen Law Firm, P.A.
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
April 25, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm
April 21, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
ALDX Investors Have Opportunity to Join Aldeyra Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
April 21, 2025
From
The Schall Law Firm
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
April 21, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
April 17, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Aldeyra Therapeutics Appoints Chip Clark to Board of Directors
April 17, 2025
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm
April 15, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
